HBM Healthcare Investments (SIX: HBMN)

Currency in

Last close As at 30/11/2023


4.00 (1.97%)

Market capitalisation


HBMN aims to generate long-term capital gains through direct investments in emerging private and public companies in biotechnology, human medicine, diagnostics, medical technology and related areas.

Latest Insights

View More

Investment Companies | Review

HBM Healthcare Investments — Looking ahead to renewed opportunities

Investment Companies | Review

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies | Flash note

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn

Investment Companies | Review

HBM Healthcare Investments — Keeping calm amid the market turmoil

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (1.0) (12.1) (14.5)
Relative (6.0) (12.4) (9.3)
52 week high/low €275.0/€192.2


HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).



Investment Companies

European equities


Investment Companies

Listed Private Equity


Investment Companies

Vietnamese equities: Due a comeback?



IPO apocalypse

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free